Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 8c; Net R&D Expenses Halved

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15).

Net R&D expenses for the fourth quarter of 2015 were $0.8 million, compared with $1.6 million for the fourth quarter of 2014.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance